Dendritic cell vaccines.
Dendritic cells are antigen-presenting cells that have been shown to stimulate tumor antigen-specific T cell responses in preclinical studies. Consequently, there has been intense interest in developing dendritic cell based cancer vaccines. A variety of methods for generating dendritic cells, loading them with tumor antigens, and administering them to patients have been described. In recent years, a number of early phase clinical trials have been performed and have demonstrated the safety and feasibility of dendritic cell immunotherapies. A number of these trials have generated valuable preliminary data regarding the clinical and immunologic response to DC-based immunotherapy. The emphasis of dendritic cell immunotherapy research is increasingly shifting toward the development of strategies to increase the potency of dendritic cell vaccine preparations.
Published In/Presented At
Mosca, P. J., Lyerly, H. K., Clay, T. M., Morse, M. A., & Lyerly, H. K. (2007). Dendritic cell vaccines. Frontiers in bioscience : a journal and virtual library, 12, 4050–4060. https://doi.org/10.2741/2371
Medicine and Health Sciences
Department of Medicine